Drugs / Pentavalent rotavirus vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03537508 | Apr 2018 → Sep 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02286895 | Oct 2014 → Mar 2015 | Rotavirus infection | PATH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pentavalent rotavirus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02286895 ↗ |
| Known as | PRV | “Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg) plus one oral dose of pentavalent rotavirus vaccine (PRV).” NCT02286895 ↗ |
| Modality | Vaccine | “Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal...” NCT02286895 ↗ |
| Route | Oral | “This vaccine was administered orally.” NCT02286895 ↗ |